BACKGROUND:Actinic keratosis is a precursor to cutaneous squamous cell carcinoma. Long treatment durations and severe side effects have limited the efficacy of current actinic keratosis treatments. Thymic stromal lymphopoietin (TSLP) is an epithelium-derived cytokine that induces a robust antitumor immunity in barrier-defective skin. Here, we investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic keratosis. METHODS: The mechanism of calcipotriol action against skin carcinogenesis was examined in genetically engineered mouse models. The efficacy and safety of 0.005% calcipotriol ointment combined with 5% 5-FU cream were compared with Vaseline plus 5-FU for the field treatment of actinic keratosis in a randomized, double-blind clinical trial involving 131 participants. The assigned treatment was self-applied to the entirety of the qualified anatomical sites (face, scalp, and upper extremities) twice daily for 4 consecutive days. The percentage of reduction in the number of actinic keratoses (primary outcome), local skin reactions, and immune activation parameters were assessed. RESULTS:Calcipotriol suppressed skin cancer development in mice in a TSLP-dependent manner. Four-day application of calcipotriol plus 5-FU versus Vaseline plus 5-FU led to an 87.8% versus 26.3% mean reduction in the number of actinic keratoses in participants (P < 0.0001). Importantly, calcipotriol plus 5-FU treatment induced TSLP, HLA class II, and natural killer cell group 2D (NKG2D) ligand expression in the lesional keratinocytes associated with a marked CD4+ T cell infiltration, which peaked on days 10-11 after treatment, without pain, crusting, or ulceration. CONCLUSION: Our findings demonstrate the synergistic effects of calcipotriol and 5-FU treatment in optimally activating a CD4+ T cell-mediated immunity against actinic keratoses and, potentially, cancers of the skin and other organs. TRIAL REGISTRATION: ClinicalTrials.gov NCT02019355. FUNDING: Not applicable (investigator-initiated clinical trial).
RCT Entities:
BACKGROUND:Actinic keratosis is a precursor to cutaneous squamous cell carcinoma. Long treatment durations and severe side effects have limited the efficacy of current actinic keratosis treatments. Thymic stromal lymphopoietin (TSLP) is an epithelium-derived cytokine that induces a robust antitumor immunity in barrier-defective skin. Here, we investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic keratosis. METHODS: The mechanism of calcipotriol action against skin carcinogenesis was examined in genetically engineered mouse models. The efficacy and safety of 0.005% calcipotriol ointment combined with 5% 5-FU cream were compared with Vaseline plus 5-FU for the field treatment of actinic keratosis in a randomized, double-blind clinical trial involving 131 participants. The assigned treatment was self-applied to the entirety of the qualified anatomical sites (face, scalp, and upper extremities) twice daily for 4 consecutive days. The percentage of reduction in the number of actinic keratoses (primary outcome), local skin reactions, and immune activation parameters were assessed. RESULTS:Calcipotriol suppressed skin cancer development in mice in a TSLP-dependent manner. Four-day application of calcipotriol plus 5-FU versus Vaseline plus 5-FU led to an 87.8% versus 26.3% mean reduction in the number of actinic keratoses in participants (P < 0.0001). Importantly, calcipotriol plus 5-FU treatment induced TSLP, HLA class II, and natural killer cell group 2D (NKG2D) ligand expression in the lesional keratinocytes associated with a marked CD4+ T cell infiltration, which peaked on days 10-11 after treatment, without pain, crusting, or ulceration. CONCLUSION: Our findings demonstrate the synergistic effects of calcipotriol and 5-FU treatment in optimally activating a CD4+ T cell-mediated immunity against actinic keratoses and, potentially, cancers of the skin and other organs. TRIAL REGISTRATION: ClinicalTrials.gov NCT02019355. FUNDING: Not applicable (investigator-initiated clinical trial).
Authors: C William Hanke; Kenneth R Beer; Eggert Stockfleth; Jason Wu; Theodore Rosen; Sharon Levy Journal: J Am Acad Dermatol Date: 2010-02-04 Impact factor: 11.527
Authors: E Stockfleth; K Peris; C Guillen; R Cerio; N Basset-Seguin; P Foley; J Sanches; A Culshaw; S Erntoft; M Lebwohl Journal: J Eur Acad Dermatol Venereol Date: 2014-07-27 Impact factor: 6.166
Authors: Christine Guo Lian; Ericka M Bueno; Scott R Granter; Alvaro C Laga; Arturo P Saavedra; William M Lin; Joseph S Susa; Qian Zhan; Anil K Chandraker; Stefan G Tullius; Bohdan Pomahac; George F Murphy Journal: Mod Pathol Date: 2014-01-17 Impact factor: 7.842
Authors: Lindsey Warino; Mark Tusa; Fabian Camacho; Hoa Teuschler; Alan B Fleischer; Steven R Feldman Journal: Dermatol Surg Date: 2006-08 Impact factor: 3.398
Authors: Mei Li; Pierre Hener; Zhikun Zhang; Shigeaki Kato; Daniel Metzger; Pierre Chambon Journal: Proc Natl Acad Sci U S A Date: 2006-07-31 Impact factor: 11.205
Authors: Iñigo Martincorena; Amit Roshan; Moritz Gerstung; Peter Ellis; Peter Van Loo; Stuart McLaren; David C Wedge; Anthony Fullam; Ludmil B Alexandrov; Jose M Tubio; Lucy Stebbings; Andrew Menzies; Sara Widaa; Michael R Stratton; Philip H Jones; Peter J Campbell Journal: Science Date: 2015-05-22 Impact factor: 47.728
Authors: Antony P B Black; Michael R Ardern-Jones; Victoria Kasprowicz; Paul Bowness; Louise Jones; Abigail S Bailey; Graham S Ogg Journal: Eur J Immunol Date: 2007-06 Impact factor: 5.532
Authors: Abby R Rosenberg; Mary Tabacchi; Kenneth H Ngo; Michael Wallendorf; Ilana S Rosman; Lynn A Cornelius; Shadmehr Demehri Journal: JCI Insight Date: 2019-03-21
Authors: Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Zorica Janjetovic; Tae-Kang Kim; Radomir M Slominski; Robert C Tuckey; Rebecca S Mason; Anton M Jetten; Purushotham Guroji; Jörg Reichrath; Craig Elmets; Mohammad Athar Journal: Adv Exp Med Biol Date: 2020 Impact factor: 2.622
Authors: Gabriel E Molina; Saami Khalifian; Jamie L Mull; Lu Chen; Ilana S Rosman; Beverly E Faulkner-Jones; Kenneth H Ngo; Shadmehr Demehri; Lynn A Cornelius; Peggy A Wu Journal: JAMA Dermatol Date: 2019-05-01 Impact factor: 10.282